These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 15654352

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.
    Skert C, Patriarca F, Sperotto A, Cerno M, Filì C, Zaja F, Stocchi R, Geromin A, Damiani D, Fanin R.
    Haematologica; 2006 Feb; 91(2):258-61. PubMed ID: 16461315
    [Abstract] [Full Text] [Related]

  • 3. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
    Ma SY, Au WY, Lie AK, Ng IO, Leung AY, Tse EW, Liang RH, Lau GK, Kwong YL.
    Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
    [Abstract] [Full Text] [Related]

  • 4. Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion.
    Voltarelli JC, Ahmed H, Paton EJ, Stracieri AB, Holman P, Bashey A, Coutinho M, Simoes BP, Ball ED, Carrier E.
    Bone Marrow Transplant; 2001 Jul; 28(1):97-9. PubMed ID: 11498752
    [Abstract] [Full Text] [Related]

  • 5. Myositis, polyserositis with a large pericardial effusion and constrictive pericarditis as manifestations of chronic graft-versus-host disease after non-myeloablative peripheral stem cell transplantation and subsequent donor lymphocyte infusion.
    Silberstein L, Davies A, Kelsey S, Foran J, Murrell C, D'Cruz D, Vinnicombe S, Norton A, Cavenagh J.
    Bone Marrow Transplant; 2001 Jan; 27(2):231-3. PubMed ID: 11281399
    [Abstract] [Full Text] [Related]

  • 6. Koebnerizing sclerodermatous graft-versus-host disease caused by donor lymphocyte infusion and interferon-alpha.
    White JM, Devereux S, Pagliuca A, Salisbury JR, du Vivier AW, Creamer D.
    Br J Dermatol; 2006 Sep; 155(3):621-3. PubMed ID: 16911292
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Graft-versus-host disease: case report and review of literature.
    Jing X, Halat S, Meleg-Smith S.
    J La State Med Soc; 2006 Sep; 158(1):20-4. PubMed ID: 16602481
    [Abstract] [Full Text] [Related]

  • 9. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
    Bridge AT, Nelson RP, Schwartz JE, Mirowski GW, Billings SD.
    Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma.
    Ayuk F, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer HG, Zabelina T, Zander AR, Kröger N.
    Leukemia; 2004 Mar; 18(3):659-62. PubMed ID: 14671630
    [No Abstract] [Full Text] [Related]

  • 11. Severe intestinal graft versus host disease after donor lymphocyte infusion; response to extracorporeal photochemotherapy.
    Vural F, Donmez A, Doganavşargil B, Cagýrgan S, Alper H, Tombuloglu M.
    Transfus Apher Sci; 2005 Oct; 33(2):129-33. PubMed ID: 16150645
    [Abstract] [Full Text] [Related]

  • 12. Chronic graft-versus-host disease: how can we release Prometheus?
    Teshima T, Wynn TA, Soiffer RJ, Matsuoka K, Martin PJ.
    Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):142-50. PubMed ID: 18162235
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 15. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
    Moreno-Romero JA, Fernández-Avilés F, Carreras E, Rovira M, Martínez C, Mascaró JM.
    Arch Dermatol; 2008 Sep; 144(9):1106-9. PubMed ID: 18794453
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
    Creamer D, Martyn-Simmons CL, Osborne G, Kenyon M, Salisbury JR, Devereux S, Pagliuca A, Ho AY, Mufti GJ, du Vivier AW.
    Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
    [Abstract] [Full Text] [Related]

  • 19. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G, Truitt RL, Johnson BD.
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.